|Print Page Close Window|
MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
11/15/17Preclinical Studies with MyoKardia’s Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance
NASDAQ GS | MYOK (Common Stock)
$54.00 + 0.05
01/22/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.